Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance.
Liver Int
; 33(4): 642-6, 2013 Apr.
Article
en En
| MEDLINE
| ID: mdl-23346997
ABSTRACT
AIM:
Few cases of primary entecavir resistance in chronic hepatitis B patients have been reported to date. The serial profiling of the HBV polymerase gene mutations from a treatment-naive patient who developed drug resistance after 32 months of entecavir therapy is presented here.DESIGN:
Serum samples were collected at multiple time points from before the start of therapy to virological and biochemical breakthrough. The evolution of the hepatitis B virus polymerase gene mutations was analysed with commercial line probe assay and pyrosequencing.RESULTS:
Drug resistance mutation analysis by pyrosequencing revealed a two-step process in the selection of drug resistance. The patient had a good initial response to entecavir 0.5 mg/day. A partially resistant HBV strain first emerged as the predominant species from as early as 2 weeks. After a period of non-compliance to therapy, there was virological breakthrough, which resolved on restarting entecavir. Shortly after, there was secondary failure of entecavir therapy, caused by a new resistant strain carrying all three mutations required.CONCLUSION:
In this patient, pre-existence of minor population of partially resistant viral strains and treatment non-compliance probably contributed to his development of primary entecavir resistance.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Antivirales
/
Productos del Gen pol
/
Virus de la Hepatitis B
/
Farmacorresistencia Viral
/
Guanina
/
Hepatitis B
/
Mutación
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Liver Int
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2013
Tipo del documento:
Article
País de afiliación:
Singapur